Glaxo Profits Reflect Strong Sterling

04/25/07 - 03:27 PM EDT

Robert Steyer

Generic-drug competition played a key role in flat earnings and slipping sales during the first quarter for GlaxoSmithKline(GSK Quote).

The British drug giant said Wednesday that first-quarter operating profit was flat vs. the year-ago quarter; net earnings per share rose 2%; and revenue declined 4% when measured in British pounds sterling.

However, when measured in constant exchange rates, GlaxoSmithKline said operating profit rose 11%, net earnings per share gained 14% and revenue gained 4%. The weak U.S. dollar had a significant impact. One British pound was worth $1.96 during the quarter, up from $1.75 in the year-ago quarter; the pound also advanced vs. the Japanese yen and the euro.

Translated into U.S. dollars, GlaxoSmithKline reported a first-quarter operating profit of $4.25 billion, net earnings per share of 53 cents and revenue of $10.96 billion.

The constant-exchange rate data are "very encouraging" and show that the company "will continue to deliver strong earnings performance," said CEO Jean-Pierre Garnier. He reiterated a full-year earnings-per-share forecast of 8% to 10% growth in constant exchange rates.

Among major products, sales of the Advair asthma medication rose 11% to $1.64 billion vs. the year-ago quarter when measured in constant exchange rates. The herpes drug Valtrex gained 22% to $439 million, while the combined sales of several HIV/AIDS drugs slipped 3% to $704 million.

< Previous
1 2
Your Recent Quotes: Quote Up0 | Quote Down0
 
Dow S&P 500 NASDAQ
Oil*
61.06
8,191.41
883.61
1,756.33
10 Yr
3.41%
13.00
4.05
9.16
+0.16%
+0.46%
+0.52%
Data delayed 20 min
Get Jim Cramer's Free Newsletter

The Daily Booyah!
Get your daily dose of Cramer in your inbox.
Submit
We respect your privacy.

Premium Stock Ideas
Access Action Alerts Plus to find out Cramer's latest picks now!

Brokerage Partners